Skip to content

Evaluating the effectiveness of fractional co2 laser combined with platelet rich plasma (PRP) injection compared to fractional co2 laser combined with injectable hyaluronic acid in the treatment of vaginal dryness

Evaluating the effectiveness of fractional co2 laser combined with platelet rich plasma (PRP) injection compared to fractional co2 laser combined with injectable hyaluronic acid in the treatment of vaginal dryness

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180409039247N13
Enrollment
120
Registered
2025-11-26
Start date
2025-12-22
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal dryness. Menopausal and female climacteric states

Interventions

Intervention 1: Intervention group 1: Fractional CO2 laser + Platelet-Rich Plasma (PRP) injection (4 sessions, 3-week intervals). Intervention 2: Intervention group:ntervention group 2: Fractional CO2

Sponsors

Tehran University of Medical Sciences - Research Assistant
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Vaginal dryness Vaginal burning Dyspareunia Dissatisfaction with topical estrogen treatment menopause

Exclusion criteria

Exclusion criteria: Drug addictionSmokingAlcohol consumption Hormone replacement therapy within the past 6 months Acute or recurrent genitourinary tract infection

Design outcomes

Primary

MeasureTime frame
The main outcome variable is the improvement of vaginal dryness symptoms, including dyspareunia, burning, libido, vulvar discomfort, discharge, urinary infections, and post-coital bleeding, assessed over one year of follow-up. Timepoint: Primary outcome variables will be assessed at baseline (before intervention), and then at 1 month, 3 months, 6 months, and 12 months after completion of the intervention sessions. Method of measurement: The primary outcome will be measured using the Vaginal Health Index Score (VHI) assessed by a blinded gynecologist and a Visual Analogue Scale (VAS) for patient-reported symptoms such as dryness and dyspareunia. These tools will be applied at baseline and repeated at 1, 3, 6, and 12 months after the intervention to evaluate efficacy and durability.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarjan Ghaemibidgoli

Tehran University of Medical Sciences

marjan_ghaemi@yahoo.com+98 21 8800 4858

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026